Breast cancer is the most common tumor affecting females globally. Among the sub-types, Triple-Negative Breast Cancer (TNBC) remains the most aggressive and has the worst prognosis, decreased overall survival rate and no targeted therapy available. Therefore, this study’s objective was to compare and contrast the effects of continuous low-dose of BIBR 1532 (GV1), a novel analogue of BIBR 1532 (GV6) developed at GVSU, and Doxorubicin on TNBC (MDAMB 231) breast cancer cells. MDAMB 231 cells were seeded (5.0x105 cells/flask) and supplemented with GV1 or GV6 or Doxorubicin (Dox) or a combination of Dox+GV1 or Dox+GV6 for 21 days (n=4-8). The number of viable cells decreased by 55% (P<0.05) and 60% (P<0.05) in the GV6+Dox and GV1+Dox compared to Control by day 21, respectively. Our results indicate that continuous low dose anti-telomerase and chemotherapeutic drugs do inhibit breast cancer cell proliferation and merits further investigation.
Faculty Mentor: Osman Patel, Cell and Molecular Biology